Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.60 |
| ▸ | GUSB | P08236 | 10/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252815 | 1.00 | DGAT1 (0.60) | DGAT1GUSBEGFRERBB2SIRT2 | |
| SCHEMBL10299680 | 0.93 | DGAT1 (0.62) | DGAT1GUSB | |
| SCHEMBL1250444 | 0.92 | DGAT1 (0.63) | DGAT1GUSB | |
| SCHEMBL1252194 | 0.90 | DGAT1 (0.75) | DGAT1GUSBEGFRERBB2CHEK2 | |
| SCHEMBL1250496 | 0.85 | DGAT1 (0.80) | DGAT1GUSBEGFRERBB2SIRT2 | |
| SCHEMBL10299681 | 0.80 | DGAT1 (0.81) | DGAT1GUSBEGFRERBB2SIRT2 | |
| SCHEMBL1252721 | 0.80 | DGAT1 (0.79) | DGAT1GUSBEGFRERBB2 | |
| SCHEMBL10299677 | 0.78 | DGAT1 (0.83) | DGAT1GUSBCHEK2 | |
| SCHEMBL1252723 | 0.78 | DGAT1 (0.63) | DGAT1GUSBEGFRERBB2SIRT2 | |
| SCHEMBL31326544 | 0.78 | DGAT1 (0.63) | DGAT1GUSBEGFRERBB2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |